Inhibitory effect of somatostatin on inflammation and nociception

Pharmacology and Therapeutics

Volumn 112, Issue 2, 2006, Pages 440-456

  Pintér, Erika ^a   Helyes, Zsuzsanna ^a   Szolcsányi, János ^a  

^a UNIVERSITY OF PÉCS   (Hungary)

Author keywords

Immune cells; Inflammation; Neuropeptides; Nociception; Somatostatin; sst receptors

Indexed keywords

ANGIOPEPTIN; ANTIINFLAMMATORY AGENT; CYCLOSOMATOSTATIN; DEXTRO PHENYLALANYLCYSTEINYLTYROSYL DEXTRO TRYPTOPHYLLYSYLCYSTEINYLTHREONINAMIDE 2,6 DISULFIDE; DICLOFENAC; MEMBRANE RECEPTOR; MORPHINE; NEUROPEPTIDE; OCTAPEPTIDE; OCTREOTIDE; PARACETAMOL; PEPTIDE DERIVATIVE; SOMATOSTATIN; SOMATOSTATIN RECEPTOR; UNCLASSIFIED DRUG; VAPREOTIDE;

ACROMEGALY; ANALGESIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; CANCER INHIBITION; CLINICAL TRIAL; DIARRHEA; DRUG EFFECT; DRUG HALF LIFE; DRUG SAFETY; GALLBLADDER DISEASE; HUMAN; IMMUNOCOMPETENT CELL; INFLAMMATION; INFLAMMATORY DISEASE; MUSCLE CRAMP; NAUSEA; NERVE ENDING; NEUROPATHY; NOCICEPTION; NONHUMAN; PAIN; PRIORITY JOURNAL; REVIEW; SENSORY NERVE CELL; TARGET CELL; VASCULAR ENDOTHELIUM;

ANALGESICS; ANTI-INFLAMMATORY AGENTS; HUMANS; INFLAMMATION; NEUROPEPTIDES; NOCICEPTORS; RECEPTORS, SOMATOSTATIN; SENSATION; SOMATOSTATIN;

EID: 33749443206     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2006.04.010     Document Type: Review

References (177)

1. Adams R.L., Adams I.P., Lindow S.W., Zhong W., and Atkin S.L. Somatostatin receptors 2 and 5 are preferentially expressed in proliferating endothelium. Br J Cancer 92 (2005) 1493-1498
2. Almasi R., Petho G., Bolcskei K., and Szolcsanyi J. Effect of resiniferatoxin on the noxious heat threshold temperature in the rat: a novel heat allodynia model sensitive to analgesics. Br J Pharmacol 139 (2003) 49-58
3. Barber D.L., McGuire M.E., and Ganz M.B. Beta-adrenergic and somatostatin receptors regulate Na-H exchange independent of cAMP. J Biol Chem 264 (1989) 21038-21042
4. Bartho L., and Szolcsanyi J. Opiate agonists inhibit neurogenic plasma extravasation in the rat. Eur J Pharmacol 73 (1981) 101-104
5. Basbaum A.I. Distinct neurochemical features of acute and persistent pain. Proc Natl Acad Sci U S A 96 (1999) 7739-7743
6. Bayliss W.M. The Vaso-Motor System (1923), Longmans Green, London
7. Berczi I., Chalmers I.M., Nagy E., and Warrington R.J. The immune effects of neuropeptides. Baillieres Clin Rheumatol 10 (1996) 227-257
8. Berman A.S., Chancellor-Freeland C., Zhu G., and Black P.H. Substance P primes murine peritoneal macrophages for an augmented proinflammatory cytokine response to lipopolysaccharide. Neuroimmunomodulation 3 (1996) 141-149
9. Blum A.M., Metwali A., Mathew R.C., Elliott D., and Weinstock J.V. Substance P and somatostatin can modulate the amount of IgG2a secreted in response to schistosome egg antigens in murine schistosomiasis mansoni. J Immunol 151 (1993) 6994-7004
10. Bolcskei K., Helyes Z., Szabo A., Sandor K., Elekes K., Nemeth J., et al. Investigation of the role of TRPV1 receptors in acute and chronic nociceptive processes using gene-deficient mice. Pain 117 (2005) 368-376
11. Brazeau P. Somatostatin: a peptide with unexpected physiologic activities. Am J Med 81 (1986) 8-13
12. Burgess J.R., Shepherd J.J., Murton F.J., Parameswaran V., and Greenaway T.M. Effective control of bone pain by octreotide in a patient with metastatic gastrinoma. Med J Aust 164 (1996) 725-727
13. Buscail L., Delesque N., Esteve J.P., Saint-Laurent N., Prats H., Clerc P., et al. Stimulation of tyrosine phosphatase and inhibition of cell proliferation by somatostatin analogues: mediation by human somatostatin receptor subtypes SSTR1 and SSTR2. Proc Natl Acad Sci U S A 91 (1994) 2315-2319
14. Carlton S.M., Du J., Davidson E., Zhou S., and Coggeshall R.E. Somatostatin receptors on peripheral primary afferent terminals: inhibition of sensitized nociceptors. Pain 90 (2001) 233-244
15. Carlton S.M., Du J., Zhou S., and Coggeshall R.E. Tonic control of peripheral cutaneous nociceptors by somatostatin receptors. J Neurosci 21 (2001) 4042-4049
16. Carlton S.M., Zhou S., Kraemer B., and Coggeshall R.E. A role for peripheral somatostatin receptors in counter-irritation-induced analgesia. Neuroscience 120 (2003) 499-508
17. Carlton S.M., Zhou S., Du J., Hargett G.L., Ji G., and Coggeshall R.E. Somatostatin modulates the transient receptor potential vanilloid 1 (TRPV1) ion channel. Pain 110 (2004) 616-627
18. Caterina M.J., Schumacher M.A., Tominaga M., Rosen T.A., Levine J.D., and Julius D. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 389 (1997) 816-824
19. Chapman V., and Dickenson A.H. The effects of sandostatin and somatostatin on nociceptive transmission in the dorsal horn of the rat spinal cord. Neuropeptides 23 (1992) 147-152
20. Chowers Y., Cahalon L., Lahav M., Schor H., Tal R., Bar-Meir S., et al. Somatostatin through its specific receptor inhibits spontaneous and TNF-alpha- and bacteria-induced IL-8 and IL-1 beta secretion from intestinal epithelial cells. J Immunol 165 (2000) 2955-2961
21. Chrubasik J., Meynadier J., Blond S., Scherpereel P., Ackerman E., Weinstock M., et al. Somatostatin, a potent analgesic. Lancet 2 (1984) 1208-1209
22. Chrubasik J., Meynadier J., Scherpereel P., and Wunsch E. The effect of epidural somatostatin on postoperative pain. Anesth Analg 64 (1985) 1085-1088
23. Corsi M.M., Ticozzi C., Netti C., Fulgenzi A., Tiengo M., Gaja G., et al. The effect of somatostatin on experimental inflammation in rats. Anesth Analg 85 (1997) 1112-1115
24. Csaba Z., and Dournaud P. Cellular biology of somatostatin receptors. Neuropeptides 35 (2001) 1-23
25. Curtis S.B., Hewitt J., Yakubovitz S., Anzarut A., Hsiang Y.N., and Buchan A.M. Somatostatin receptor subtype expression and function in human vascular tissue. Am J Physiol Heart Circ Physiol 278 (2000) H1815-H1822
26. Dalm V.A., van Hagen P.M., van Koetsveld P.M., Achilefu S., Houtsmuller A.B., Pols D.H., et al. Expression of somatostatin, cortistatin, and somatostatin receptors in human monocytes, macrophages, and dendritic cells. Am J Physiol Endocrinol Metab 285 (2003) E344-E353
27. Dalm V.A., van Hagen P.M., van Koetsveld P.M., Langerak A.W., van der Lely A.J., Lamberts S.W., et al. Cortistatin rather than somatostatin as a potential endogenous ligand for somatostatin receptors in the human immune system. J Clin Endocrinol Metab 88 (2003) 270-276
28. Dalm V.A., Hofland L.J., Mooy C.M., Waaijers M.A., van Koetsveld P.M., Langerak A.W., et al. Somatostatin receptors in malignant lymphomas: targets for radiotherapy?. J Nucl Med 45 (2004) 8-16
29. Dasgupta P. Somatostatin analogues: multiple roles in cellular proliferation, neoplasia, and angiogenesis. Pharmacol Ther 102 (2004) 61-85
30. Davies N., Yates J., Kynaston H., Taylor B.A., and Jenkins S.A. Effects of octreotide on liver regeneration and tumour growth in the regenerating liver. J Gastroenterol Hepatol 12 (1997) 47-53
31. Davis J.B., Gray J., Gunthorpe M.J., Hatcher J.P., Davey P.T., Overend P., et al. Vanilloid receptor-1 is essential for inflammatory thermal hyperalgesia. Nature 405 (2000) 183-187
32. Deer T.E., Kim C.K., Bowman R.G., Stewart C.D., Norris M., Khan Y., et al. The use of continuous intrathecal infusion of octreotide in patient with chronic pain of noncancer origin: an evaluation of side-effects and toxicity in a prospective double-blind fashion. Neuromodulation 8 (2005) 171-175
33. de Franchis R. Somatostatin, somatostatin analogues and other vasoactive drugs in the treatment of bleeding oesophageal varices. Dig Liver Dis 36 Suppl. 1 (2004) S93-S100
34. Dellemijn P. Are opioids effective in relieving neuropathic pain?. Pain 80 (1999) 453-462
35. Dong Z.Q., Xie H., Ma F., Li W.M., Wang Y.Q., and Wu G.C. Effects of electroacupuncture on expression of somatostatin and preprosomatostatin mRNA in dorsal root ganglions and spinal dorsal horn in neuropathic pain rats. Neurosci Lett 385 (2005) 189-194
36. Duet M., and Liote F. Somatostatin and somatostatin analog scintigraphy: any benefits for rheumatology patients?. Joint Bone Spine 71 (2004) 530-535
37. Eglezos A., Andrews P.V., and Helme R.D. In vivo inhibition of the rat primary antibody response to antigenic stimulation by somatostatin. Immunol Cell Biol 71 Pt 2 (1993) 125-129
38. Elliott D.E., Li J., Blum A.M., Metwali A., Patel Y.C., and Weinstock J.V. SSTR2A is the dominant somatostatin receptor subtype expressed by inflammatory cells, is widely expressed and directly regulates T cell IFN-gamma release. Eur J Immunol 29 (1999) 2454-2463
39. Eschalier A., Aumaitre O., Ardid D., Fialip J., and Duchene-Marullaz P. Long-lasting antinociceptive effect of RC-160, a somatostatin analog, in mice and rats. Eur J Pharmacol 199 (1991) 119-121
40. Fehlmann D., Langenegger D., Schuepbach E., Siehler S., Feuerbach D., and Hoyer D. Distribution and characterisation of somatostatin receptor mRNA and binding sites in the brain and periphery. J Physiol (Paris) 94 (2000) 265-281
41. Fioravanti A., Govoni M., La Montagna G., Perpignano G., Tirri G., Trotta F., et al. Somatostatin 14 and joint inflammation: evidence for intraarticular efficacy of prolonged administration in rheumatoid arthritis. Drugs Exp Clin Res 21 (1995) 97-103
42. Florio T., and Schettini G. Multiple intracellular effectors modulate physiological functions of the cloned somatostatin receptors. J Mol Endocrinol 17 (1996) 89-100
43. Freedman J., Post C., Kahrstrom J., Ohlen A., Mollenholt P., Owman C., et al. Vasoconstrictor effects in spinal cord of the substance P antagonist [D-Arg, D-Trp7,9 Leu11]-substance P (Spantide) and somatostatin and interaction with thyrotropin releasing hormone. Neuroscience 27 (1988) 267-278
44. Gaudillere A., Bernard C., Abello J., Schmitt D., Claudy A., and Misery L. Human normal dermal fibroblasts express somatostatin receptors. Exp Dermatol 8 (1999) 267-273
45. Gaumann D.M., Yaksh T.L., Post C., Wilcox G.L., and Rodriguez M. Intrathecal somatostatin in cat and mouse studies on pain, motor behavior, and histopathology. Anesth Analg 68 (1989) 623-632
46. Gibson S.J., Polak J.M., Katagiri T., Su H., Weller R.O., Brownell D.B., et al. A comparison of the distributions of eight peptides in spinal cord from normal controls and cases of motor neurone disease with special reference to Onuf's nucleus. Brain Res 474 (1988) 255-278
47. Grant A. Leukocytes and neurogenic inflammation. Inflammaopharmacology 9 (2002) 403-420
48. Green P.G., Basbaum A.I., and Levine J.D. Sensory neuropeptide interactions in the production of plasma extravasation in the rat. Neuroscience 50 (1992) 745-749
49. Gronbaek H., Vogel I., Osterby R., Lancranjan I., Flyvbjerg A., and Orskov H. Effect of octreotide, captopril or insulin on renal changes and UAE in long-term experimental diabetes. Kidney Int 53 (1998) 173-180
50. Gu Y.Z., Brown P.J., Loose-Mitchell D.S., Stork P.J., and Schonbrunn A. Development and use of a receptor antibody to characterize the interaction between somatostatin receptor subtype 1 and G proteins. Mol Pharmacol 48 (1995) 1004-1014
51. Gulya K., Pelton J.T., Hruby V.J., and Yamamura H.I. Cyclic somatostatin octapeptide analogues with high affinity and selectivity toward mu opioid receptors. Life Sci 38 (1986) 2221-2229
52. Helmchen C., Fu Q.G., and Sandkuhler J. Inhibition of spinal nociceptive neurons by microinjections of somatostatin into the nucleus raphe magnus and the midbrain periaqueductal gray of the anesthetized cat. Neurosci Lett 187 (1995) 137-141
53. Helyes Z., Pinter E., and Szolcsanyi J. TT-232. Drugs Future 30 (2005) 1-9
54. Helyes Z., Pinter E., Szolcsanyi J., and Horvath J. Anti-inflammatory and antinociceptive effect of different somatostatin-analogs. Neurobiology (Bp) 4 (1996) 115-117
55. Helyes Z., Than M., Oroszi G., Pinter E., Nemeth J., Keri G., et al. Anti-nociceptive effect induced by somatostatin released from sensory nerve terminals and by synthetic somatostatin analogues in the rat. Neurosci Lett 278 (2000) 185-188
56. Helyes Z., Pinter E., Nemeth J., Keri G., Than M., Oroszi G., et al. Anti-inflammatory effect of synthetic somatostatin analogues in the rat. Br J Pharmacol 134 (2001) 1571-1579
57. Helyes Z., Szabo A., Nemeth J., Jakab B., Pinter E., Banvolgyi A., et al. Antiinflammatory and analgesic effects of somatostatin released from capsaicin-sensitive sensory nerve terminals in a Freund's adjuvant-induced chronic arthritis model in the rat. Arthritis Rheum 50 (2004) 1677-1685
58. Heppelmann B., and Pawlak M. Inhibitory effect of somatostatin on the mechanosensitivity of articular afferents in normal and inflamed knee joints of the rat. Pain 73 (1997) 377-382
59. Heppelmann B., and Pawlak M. Peripheral application of cyclo-somatostatin, a somatostatin antagonist, increases the mechanosensitivity of rat knee joint afferents. Neurosci Lett 259 (1999) 62-64
60. Hipkin R.W., Friedman J., Clark R.B., Eppler C.M., and Schonbrunn A. Agonist-induced desensitization, internalization, and phosphorylation of the sst2A somatostatin receptor. J Biol Chem 272 (1997) 13869-13876
61. Hiruma K., Koike T., Nakamura H., Sumida T., Maeda T., Tomioka H., et al. Somatostatin receptors on human lymphocytes and leukaemia cells. Immunology 71 (1990) 480-485
62. Hofland L.J., Visser-Wisselaar H.A., and Lamberts S.W. Somatostatin analogs: clinical application in relation to human somatostatin receptor subtypes. Biochem Pharmacol 50 (1995) 287-297
63. Hofland L.J., Liu Q., van Koetsveld P.M., Zuijderwijk J., van der H.F., De Krijger R.R., et al. Immunohistochemical detection of somatostatin receptor subtypes sst1 and sst2A in human somatostatin receptor positive tumors. J Clin Endocrinol Metab 84 (1999) 775-780
64. Hokfelt T., Elde R., Johansson O., Luft R., Nilsson G., and Arimura A. Immunohistochemical evidence for separate populations of somatostatin-containing and substance P-containing primary afferent neurons in the rat. Neuroscience (1976) 131-136
65. Hoyer D., Bell G.I., Berelowitz M., Epelbaum J., Feniuk W., Humphrey P.P., et al. Classification and nomenclature of somatostatin receptors. Trends Pharmacol Sci 16 (1995) 86-88
66. Hukovic N., Panetta R., Kumar U., and Patel Y.C. Agonist-dependent regulation of cloned human somatostatin receptor types 1-5 (hSSTR1-5): subtype selective internalization or upregulation. Endocrinology 137 (1996) 4046-4049
67. Hukovic N., Panetta R., Kumar U., Rocheville M., and Patel Y.C. The cytoplasmic tail of the human somatostatin receptor type 5 is crucial for interaction with adenylyl cyclase and in mediating desensitization and internalization. J Biol Chem 273 (1998) 21416-21422
68. Jakobs K.H., Aktories K., and Schultz G. A nucleotide regulatory site for somatostatin inhibition of adenylate cyclase in S49 lymphoma cells. Nature 303 (1983) 177-178
69. Jancso N., Jancso-Gabor A., and Szolcsanyi J. Direct evidence for neurogenic inflammation and its prevention by denervation and by pretreatment with capsaicin. Br J Pharmacol 31 (1967) 138-151
70. Janecka A., Zubrzycka M., and Janecki T. Somatostatin analogs. J Pept Res 58 (2001) 91-107
71. Jenkins S.A., Kynaston H.G., Davies N.D., Baxter J.N., and Nott D.M. Somatostatin analogs in oncology: a look to the future. Chemotherapy 47 Suppl. 2 (2001) 162-196
72. Jenkins P.J., Emery M., Howling S.J., Evanson J., Besser G.M., and Monson J.P. Predicting therapeutic response and degree of pituitary tumour shrinkage during treatment of acromegaly with octreotide LAR. Horm Res 62 (2004) 227-232
73. Kapicioglu S., Gokce E., Kapicioglu Z., and Ovali E. Treatment of migraine attacks with a long-acting somatostatin analogue (octreotide, SMS 201-995). Cephalalgia 17 (1997) 27-30
74. Karalis K., Mastorakos G., Chrousos G.P., and Tolis G. Somatostatin analogues suppress the inflammatory reaction in vivo. J Clin Invest 93 (1994) 2000-2006
75. Kashiba H., Ueda Y., and Senba E. Coexpression of preprotachykinin-A, alpha-calcitonin gene-related peptide, somatostatin, and neurotrophin receptor family messenger RNAs in rat dorsal root ganglion neurons. Neuroscience 70 (1996) 179-189
76. Keri G., Mezo I., Vadasz Z., Horvath A., Idei M., Vantus T., et al. Structure-activity relationship studies of novel somatostatin analogs with antitumor activity. Pept Res 6 (1993) 281-288
77. Keri G., Erchegyi J., Horvath A., Mezo I., Idei M., Vantus T., et al. A tumor-selective somatostatin analog (TT-232) with strong in vitro and in vivo antitumor activity. Proc Natl Acad Sci U S A 93 (1996) 12513-12518
78. Koch B.D., Blalock J.B., and Schonbrunn A. Characterization of the cyclic AMP-independent actions of somatostatin in GH cells: I. An increase in potassium conductance is responsible for both the hyperpolarization and the decrease in intracellular free calcium produced by somatostatin. J Biol Chem 263 (1988) 216-225
79. Kolasinski S.L., Haines K.A., Siegel E.L., Cronstein B.N., and Abramson S.B. Neuropeptides and inflammation. A somatostatin analog as a selective antagonist of neutrophil activation by substance P. Arthritis Rheum 35 (1992) 369-375
80. Krulich L., Dhariwal A.P., and McCann S.M. Stimulatory and inhibitory effects of purified hypothalamic extracts on growth hormone release from rat pituitary in vitro. Endocrinology 83 (1968) 783-790
81. Kuraishi Y., Hirota N., Sato Y., Kaneko S., Satoh M., and Takagi H. Noradrenergic inhibition of the release of substance P from the primary afferents in the rabbit spinal dorsal horn. Brain Res 359 (1985) 177-182
82. Kwekkeboom D.J., and Krenning E.P. Somatostatin receptor scintigraphy in patients with carcinoid tumors. World J Surg 20 (1996) 157-161
83. Lamberts S.W., van der Lely A.J., de Herder W.W., and Hofland L.J. Somatostatin analogs: future directions. Metabolism 45 (1996) 104-106
84. Lawson S.N. Neuropeptides in morphologically and functionally identified primary afferent neurons in dorsal root ganglia: substance P. CGRP and somatostatin. Prog Brain Res 104 (1995) 161-173
85. Lembeck F., Donnerer J., and Bartho L. Inhibition of neurogenic vasodilation and plasma extravasation by substance P antagonists, somatostatin and [D-Met2,Pro5]enkephalinamide. Eur J Pharmacol 85 (1982) 171-176
86. Lewis T. The Blood Vessels of Human Skin and Their Responses (1927), Shaw, London
87. Li M., Yan S., Fisher W.E., Chen C., and Yao Q. New roles of a neuropeptide cortistatin in the immune system and cancer. World J Surg 29 (2005) 354-356
88. Lichtenauer-Kaligis E.G.R., van Hagen P.M., Lamberts S.W.J., and Hofland L.J. Somatostatin receptor subtypes in human immune cells. Eur J Endocrinol 143 (2000) S21-S25
89. Lichtenauer-Kaligis E.G., Dalm V.A., Oomen S.P., Mooij D.M., van Hagen P.M., Lamberts S.W., et al. Differential expression of somatostatin receptor subtypes in human peripheral blood mononuclear cell subsets. Eur J Endocrinol 150 (2004) 565-577
90. Lundberg J.M. Pharmacology of cotransmission in the autonomic nervous system: integrative aspects on amines, neuropeptides, adenosine triphosphate, amino acids and nitric oxide. Pharmacol Rev 48 (1996) 113-178
91. Maggi C.A. Tachykinins and calcitonin gene-related peptide (CGRP) as co-transmitters released from peripheral endings of sensory nerves. Prog Neurobiol 45 (1995) 1-98
92. Malcangio M. GDNF and somatostatin in sensory neurones. Curr Opin Pharmacol 3 (2003) 41-45
93. Matucci-Cerinic M., and Marabini S. Somatostatin treatment for pain in rheumatoid arthritis: a double blind versus placebo study in knee involvement. Med Sci Res 16 (1998) 233-234
94. Maurer R., Gaehwiler B.H., Buescher H.H., Hill R.C., and Roemer D. Opiate antagonistic properties of an octapeptide somatostatin analog. Proc Natl Acad Sci U S A 79 (1982) 4815-4817
95. Meyerhof W. The elucidation of somatostatin receptor functions: a current view. Rev Physiol Biochem Pharmacol 133 (1998) 55-108
96. Meynadier J., Chrubasik J., Dubar M., and Wunsch E. Intrathecal somatostatin in terminally ill patients. A report of two cases. Pain 23 (1985) 9-12
97. Mihara S., North R.A., and Surprenant A. Somatostatin increases an inwardly rectifying potassium conductance in guinea-pig submucous plexus neurones. J Physiol 390 (1987) 335-355
98. Miletic V., and Randic M. Neonatal rat spinal cord slice preparation: postsynaptic effects of neuropeptides on dorsal horn neurons. Dev Brain Res 2 (1982) 432-438
99. Misery L. Skin, immunity and the nervous system. Br J Dermatol 137 (1997) 843-850
100. Mollenholt P., Post C., Rawal N., Freedman J., Hokfelt T., and Paulsson I. Antinociceptive and 'neurotoxic' actions of somatostatin in rat spinal cord after intrathecal administration. Pain 32 (1988) 95-105
101. Mollenholt P., Rawal N., Gordh Jr. T., and Olsson Y. Intrathecal and epidural somatostatin for patients with cancer. Analgesic effects and postmortem neuropathologic investigations of spinal cord and nerve roots. Anesthesiology 81 (1994) 534-542
102. Moller L.N., Stidsen C.E., Hartmann B., and Holst J.J. Somatostatin receptors. Biochim Biophys Acta 1616 (2003) 1-84
103. Moore S.D., Madamba S.G., Joels M., and Siggins G.R. Somatostatin augments the M-current in hippocampal neurons. Science 239 (1988) 278-280
104. Morton C.R., Hutchison W.D., Hendry I.A., and Duggan A.W. Somatostatin: evidence for a role in thermal nociception. Brain Res 488 (1989) 89-96
105. Murase K., Nedeljkov V., and Randic M. The actions of neuropeptides on dorsal horn neurons in the rat spinal cord slice preparation: an intracellular study. Brain Res 234 (1982) 170-176
106. Muscettola M., and Grasso G. Somatostatin and vasoactive intestinal peptide reduce interferon gamma production by human peripheral blood mononuclear cells. Immunobiology 180 (1990) 419-430
107. Niedermuhlbichler M., and Wiedermann C.J. Suppression of superoxide release from human monocytes by somatostatin-related peptides. Regul Pept 41 (1992) 39-47
108. Paice J.A., Penn R.D., and Kroin J.S. Intrathecal octreotide for relief of intractable nonmalignant pain: 5-year experience with two cases. Neurosurgery 38 (1996) 203-207
109. Partsch G., and Matucci-Cerinic M. Effect of substance P and somatostatin on migration of polymorphonuclear (PMN) cells in vitro. Inflammation 16 (1992) 539-547
110. Patel Y.C. Molecular pharmacology of somatostatin receptor subtypes. J Endocrinol Invest 20 (1997) 348-367
111. Patel Y.C. Somatostatin and its receptor family. Front Neuroendocrinol 20 (1999) 157-198
112. Patel Y.C., and Reichlin S. Somatostatin in hypothalamus, extrahypothalamic brain, and peripheral tissues of the rat. Endocrinology 102 (1978) 523-530
113. Patel Y.C., Greenwood M., Kent G., Panetta R., and Srikant C.B. Multiple gene transcripts of the somatostatin receptor SSTR2: tissue selective distribution and cAMP regulation. Biochem Biophys Res Commun 192 (1993) 288-294
114. Patel Y.C., Greenwood M.T., Panetta R., Demchyshyn L., Niznik H., and Srikant C.B. The somatostatin receptor family. Life Sci 57 (1995) 1249-1265
115. Pelton J.T., Kazmierski W., Gulya K., Yamamura H.I., and Hruby V.J. Design and synthesis of conformationally constrained somatostatin analogues with high potency and specificity for mu opioid receptors. J Med Chem 29 (1986) 2370-2375
116. Perez J., Viollet C., Doublier S., Videau C., Epelbaum J., and Baud L. Somatostatin binds to murine macrophages through two distinct subsets of receptors. J Neuroimmunol 138 (2003) 38-44
117. Pinter E., and Szolcsanyi J. Inflammatory and antiinflammatory effects of antidromic stimulation of dorsal roots in the rat. Agents Actions 25 (1988) 240-242
118. Pinter E., and Szolcsanyi J. Plasma extravasation in the skin and pelvic organs evoked by antidromic stimulation of the lumbosacral dorsal roots of the rat. Neuroscience 68 (1995) 603-614
119. Pinter E., and Szolcsanyi J. Systemic anti-inflammatory effect induced by antidromic stimulation of the dorsal roots in the rat. Neurosci Lett 212 (1996) 33-36
120. Pinter E., Helyes Z., Nemeth J., Porszasz R., Petho G., Than M., et al. Pharmacological characterisation of the somatostatin analogue TT-232: effects on neurogenic and non-neurogenic inflammation and neuropathic hyperalgesia. Naunyn-Schmiedeberg's Arch Pharmacol 366 (2002) 142-150
121. Pinter E., Than M., Chu D.Q., Fogg C., and Brain S.D. Interaction between interleukin 1beta and endogenous neurokinin 1 receptor agonists in mediating plasma extravasation and neutrophil accumulation in the cutaneous microvasculature of the rat. Neurosci Lett 318 (2002) 13-16
122. Plourde V., Lembo T., Shui Z., Parker J., Mertz H., Tache Y., et al. Effects of the somatostatin analogue octreotide on rectal afferent nerves in humans. Am J Physiol 265 (1993) G742-G751
123. Pradayrol L., Jornvall H., Mutt V., and Ribet A. N-terminally extended somatostatin: the primary structure of somatostatin-28. FEBS Lett 109 (1980) 55-58
124. Pugsley T.A., and Lippmann W. Effect of somatostatin analogues and 17-alpha-dihydroequilin on rat brain opiate receptors. Res Commun Chem Pathol Pharmacol 21 (1978) 153-156
125. Randic M., and Miletic V. Depressant actions of methionine-enkephalin and somatostatin in cat dorsal horn neurones activated by noxious stimuli. Brain Res 152 (1978) 196-202
126. Reichlin S. Somatostatin. N Engl J Med 309 (1983) 1495-1501
127. Reichlin S. Somatostatin (second of two parts). N Engl J Med 309 (1983) 1556-1563
128. Reisine T., and Bell G.I. Molecular properties of somatostatin receptors. Neuroscience 67 (1995) 777-790
129. Renold F.K., Dazin P., Goetzl E.J., and Payan D.G. Interleukin-3 modulation of mouse bone marrow derived mast cell receptors for somatostatin. J Neurosci Res 18 (1987) 195-202
130. Reubi J.C., Mazzucchelli L., and Laissue J.A. Intestinal vessels express a high density of somatostatin receptors in human inflammatory bowel disease. Gastroenterology 106 (1994) 951-959
131. Reubi J.C., Waser B., Markusse H.M., Krenning E.P., VanHagen M., and Laissue J.A. Vascular somatostatin receptors in synovium from patients with rheumatoid arthritis. Eur J Pharmacol 271 (1994) 371-378
132. Rezek M., Havlicek V., Leybin L., LaBella F.S., and Friesen H. Opiate-like naloxone-reversible actions of somatostatin given intracerebrally. Can J Physiol Pharmacol 56 (1978) 227-231
133. Robas N., Mead E., and Fidock M. MrgX2 is a high potency cortistatin receptor expressed in dorsal root ganglion. J Biol Chem 278 (2003) 44400-44404
134. Rosenthal B.M., and Ho R.H. An electron microscopic study of somatostatin immunoreactive structures in lamina II of the rat spinal cord. Brain Res Bull 22 (1989) 439-451
135. Saavedra Y., and Vergara P. Somatostatin inhibits intestinal mucosal mast cell degranulation in normal conditions and during mast cell hyperplasia. Regul Pept 111 (2003) 67-75
136. Sandkuhler J., Fu Q.G., and Helmchen C. Spinal somatostatin superfusion in vivo affects activity of cat nociceptive dorsal horn neurons: comparison with spinal morphine. Neuroscience 34 (1990) 565-576
137. Scarpignato C., and Pelosini I. Somatostatin analogs for cancer treatment and diagnosis: an overview. Chemotherapy 47 Suppl. 2 (2001) 1-29
138. Schally A.V. Oncological applications of somatostatin analogues. Cancer Res 48 (1988) 6977-6985
139. Schindler M., Humphrey P.P., and Emson P.C. Somatostatin receptors in the central nervous system. Prog Neurobiol 50 (1996) 9-47
140. Schloos J., Raulf F., Hoyer D., and Bruns C. Identification and pharmacological characterization of somatostatin receptors in rat lung. Br J Pharmacol 121 (1997) 963-971
141. Scholzen T., Armstrong C.A., Bunnett N.W., Luger T.A., Olerud J.E., and Ansel J.C. Neuropeptides in the skin: interactions between the neuroendocrine and the skin immune systems. Exp Dermatol 7 (1998) 81-96
142. Scicchitano R., Dazin P., Bienenstock J., Payan D.G., and Stanisz A.M. The murine IgA-secreting plasmacytoma MOPC-315 expresses somatostatin receptors. J Immunol 141 (1988) 937-941
143. Selmer I., Schindler M., Allen J.P., Humphrey P.P., and Emson P.C. Advances in understanding neuronal somatostatin receptors. Regul Pept 90 (2000) 1-18
144. Selye H. The Mast Cells (1965), Butterworths, Washington
145. Sener G., Cetinel S., Erkanli G., Gedik N., and Yegen B.C. Octreotide ameliorates sepsis-induced pelvic inflammation in female rats by a neutrophil-dependent mechanism. Peptides 26 (2005) 493-499
146. Shimon I., and Melmed S. Diagnosis and treatment of pituitary disease. Psychother Psychosom 67 (1998) 119-124
147. Sicuteri F., Raino L., and Geppetti P. Substance P and endogenous opioids: how and where they could play a role in cluster headache. Cephalgia 3 Suppl. 1 (1983) 143-145
148. Silveri F., Morosini P., Brecciaroli D., and Cervini C. Intra-articular injection of somatostatin in knee osteoarthritis: clinical results and IGF-1 serum levels. Int J Clin Pharmacol Res 14 (1994) 79-85
149. Spampinato S., and Ferri S. Pharmacology of spinal peptides affecting sensory and motor functions: dynorphins, somatostatins and tachykinins. Pharmacol Res 23 (1991) 113-127
150. Spampinato S., Romualdi P., Candeletti S., Cavicchini E., and Ferri S. Distinguishable effects of intrathecal dynorphins, somatostatin, neurotensin and s-calcitonin on nociception and motor function in the rat. Pain 35 (1988) 95-104
151. Spina D. Modulation of sensory nerve function in the airways. Pulm Pharmacol Ther 11 (1998) 319-330
152. Strader C.D., Fong T.M., Graziano M.P., and Tota M.R. The family of G-protein-coupled receptors. FASEB J 9 (1995) 745-754
153. Szolcsanyi J., Helyes Z., Oroszi G., Nemeth J., and Pinter E. Release of somatostatin and its role in the mediation of the anti-inflammatory effect induced by antidromic stimulation of sensory fibres of rat sciatic nerve. Br J Pharmacol 123 (1998) 936-942
154. Szolcsanyi J., Pinter E., Helyes Z., Oroszi G., and Nemeth J. Systemic anti-inflammatory effect induced by counter-irritation through a local release of somatostatin from nociceptors. Br J Pharmacol 125 (1998) 916-922
155. Szolcsanyi J., Pinter E., and Helyes Z. Sensocrine function of capsaicin-sensitive nociceptors mediated by somatostatin regulates against inflammation and hyperalgesia. In: Handwerker H.O., and Brune K. (Eds). Hyperalgesia: Molecular Mechanisms and Clinical Implications. Progress in Pain Research and Management vol. 30 (2004), IASP Press, Seattle 113-128
156. Szolcsanyi J., Bolcskei K., Szabo A., Pinter E., Petho G., Elekes K., et al. Analgesic effect of TT-232, a heptapeptide somatostatin analogue, in acute pain models of the rat and the mouse and in streptozotocin-induced diabetic mechanical allodynia. Eur J Pharmacol 498 (2004) 103-109
157. Taddese A., Nah S.Y., and McCleskey E.W. Selective opioid inhibition of small nociceptive neurons. Science 270 (1995) 1366-1369
158. Taniyama Y., Suzuki T., Mikami Y., Moriya T., Satomi S., and Sasano H. Systemic distribution of somatostatin receptor subtypes in human: an immunohistochemical study. Endocr J 52 (2005) 605-611
159. Tashev R., Belcheva S., Milenov K., and Belcheva I. Antinociceptive effect of somatostatin microinjected into caudate putamen. Peptides 22 (2001) 1079-1083
160. Taura P., Planella V., Balust J., Beltran J., Anglada T., Carrero E., et al. Epidural somatostatin as an analgesic in upper abdominal surgery: a double-blind study. Pain 59 (1994) 135-140
161. ten Bokum A.M., Lichtenauer-Kaligis E.G., Melief M.J., van Koetsveld P.M., Bruns C., van Hagen P.M., et al. Somatostatin receptor subtype expression in cells of the rat immune system during adjuvant arthritis. J Endocrinol 161 (1999) 167-175
162. ten Bokum A.M., Hofland L.J., and van Hagen P.M. Somatostatin and somatostatin receptors in the immune system: a review. Eur Cytokine Netw 11 (2000) 161-176
163. Tentler J.J., Hadcock J.R., and Gutierrez-Hartmann A. Somatostatin acts by inhibiting the cyclic 3′,5′-adenosine monophosphate (cAMP)/protein kinase A pathway, cAMP response element-binding protein (CREB) phosphorylation, and CREB transcription potency. Mol Endocrinol 11 (1997) 859-866
164. Than M., Nemeth J., Szilvassy Z., Pinter E., Helyes Z., and Szolcsanyi J. Systemic anti-inflammatory effect of somatostatin released from capsaicin-sensitive vagal and sciatic sensory fibres of the rat and guinea-pig. Eur J Pharmacol 399 (2000) 251-258
165. Thermos K. Functional mapping of somatostatin receptors in the retina: a review. Vision Res 43 (2003) 1805-1815
166. Tjolsen A., Berge O.G., Hunskaar S., Rosland J.H., and Hole K. The formalin test: an evaluation of the method. Pain 51 (1992) 5-17
167. Torrecillas G., Medina J., Diez-Marques M.L., Rodriguez-Puyol D., and Rodriguez-Puyol M. Mechanisms involved in the somatostatin-induced contraction of vascular smooth muscle cells. Peptides 20 (1999) 929-935
168. van der Hoek J., Hofland L.J., and Lamberts S.W. Novel subtype specific and universal somatostatin analogues: clinical potential and pitfalls. Curr Pharm Des 11 (2005) 1573-1592
169. van Hagen P.M., Krenning E.P., Kwekkeboom D.J., Reubi J.C., Anker-Lugtenburg P.J., Lowenberg B., et al. Somatostatin and the immune and haematopoetic system; a review. Eur J Clin Invest 24 (1994) 91-99
170. van Hagen P.M., Markusse H.M., Lamberts S.W., Kwekkeboom D.J., Reubi J.C., and Krenning E.P. Somatostatin receptor imaging. The presence of somatostatin receptors in rheumatoid arthritis. Arthritis Rheum 37 (1994) 1521-1527
171. van Hagen P.M., Baarsma G.S., Mooy C.M., Ercoskan E.M., ter Averst E., Hofland L.J., et al. Somatostatin and somatostatin receptors in retinal diseases. Eur J Endocrinol 143 Suppl. 1 (2000) S43-S51
172. Volante M., Bozzalla-Cassione F., and Papotti M. Somatostatin receptors and their interest in diagnostic pathology. Endocr Pathol 15 (2004) 275-291
173. Wang H.L., Bogen C., Reisine T., and Dichter M. Somatostatin-14 and somatostatin-28 induce opposite effects on potassium currents in rat neocortical neurons. Proc Natl Acad Sci U S A 86 (1989) 9616-9620
174. Weckbecker G., Lewis I., Albert R., Schmid H.A., Hoyer D., and Bruns C. Opportunities in somatostatin research: biological, chemical and
175. Weinstock J.V. Production of neuropeptides by inflammatory cells within the granulomas of murine schistosomiasis mansoni. Eur J Clin Invest 21 (1991) 145-153
176. Wiedermann C.J., Reinisch N., and Braunsteiner H. Stimulation of monocyte chemotaxis by human growth hormone and its deactivation by somatostatin. Blood 82 (1993) 954-960
177. Xu X.J., Hao J.X., Wiesenfeld-Hallin Z., Hakanson R., Folkers K., and Hokfelt T. Spantide II, a novel tachykinin antagonist, and galanin inhibit plasma extravasation induced by antidromic C-fiber stimulation in rat hindpaw. Neuroscience 42 (1991) 731-737